We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J Replies to Complete Response for Invega NDA
J&J Replies to Complete Response for Invega NDA
February 13, 2009
Johnson & Johnson (J&J) has submitted a reply to the FDA’s complete response letter on a monthly injectable formulation of its atypical antipsychotic Invega.